Navigation Links
Glenmark’s new molecule to go through trial

Glenmark Pharmaceuticals Ltd today said its newly- found andti-diabetic/anti-obesity molecule will be put into clinical trials by later this year. Mr Glenn Saldanha, Executive Director, Glenmark pharmaceuticals, told newspersons that the company’s R&D team has established ‘proof of concept’ in animals for this molecule.//

The global diabetes market is estimated to be in the region of Rs. 400 crore. The company is scouting for partners to take the molecule into advanced phases of clinical trials. Mr. Saldahna said that the pre-clinical trials for the molecule are expected to be completed in the next six months and then the Phase I clinical studies will be initiated in Europe.

"We are scouting for contract research organisations (CROs) in Europe which will take the moleucle code named - GRC -1087 - through Phase I and probably Phase II A or early Phase II clinical trials. We might be in a position to announce the CRO in the next three months," Mr Saldanha said. The clinical trials will cost around $1 millin.
'"/>




Page: 1

Related medicine news :

1. Poisonous Parkinsons molecule discovered
2. Resistant tumors could be treated with the discovery of a new molecule within cancer cells
3. Ways to counter radiation effects with new molecule discovery
4. Same molecule found in meat, milk, tumors
5. New molecule to treat brain disorders found
6. Cell molecules behind neuro degenerative diseases
7. New anti-aging molecule could be coming up in way
8. So now here might come a memory molecule!!!
9. Lost molecule holds the key to lung cancer
10. THC molecule turns out to a boon for Alzheimer’s patient
11. Sperm washing helps couples – Breakthrough in focu
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Glenmark new molecule through trial

(Date:7/25/2008)... Management to discuss second quarter financial re.../ - Labopharm Inc. (TSX: DDS;,NASDAQ: DDSS) today ...riday, August 8 at 8:30 a.m. (ET) to discuss its s...ll report its second quarter 2008 financial,result...same day., To access the conference call by telep...
(Date:7/25/2008)...f certain cleaning products reduces lung function,... , FRIDAY, July 25 (HealthDay News) -- A clean, ...ealth, depending on what type of cleaning and air ...suggests that exposure to cleaning products or air...c compound (VOC) called 1,4 dicholorobenzene (1,4 ...
(Date:7/25/2008)...ALLAS, July 25 /PRNewswire/ -- BeaconEquity.com an... making news today., Investors can view all of th...//BeaconEquity.com/m , Today,s Trade Alerts inclu...ddleBrook Pharmaceuticals Inc. (Nasdaq: MBRK ), N... ADLR ), Affymetrix Inc. (Nasdaq: AFFX ) and,Abax...
(Date:7/25/2008)... - 180-Days of Marketing Exclusivity Beg...all/ -- Watson,Pharmaceuticals, Inc. (NYSE: WPI )...unced today that its subsidiary has commenced comm...Capsules USP product in the 40mg,strength from its...tion,with the launch, Watson has 180 days of marke...
Breaking Medicine News(10 mins):Health News:Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET) 2Health News:Health Hazards in Household Cleaners Exposed 2Health News:Health Hazards in Household Cleaners Exposed 3Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2
... has been identified by researchers that help thos...is gene seems to confer a preserving effect upon t...as presented by scientists from the Albert Einstei...sity. December 26, 2006 issue of Neurology publish...
...an holds the hand of a little boy, looking at a ro... area, which was in wreck two years ago, washed aw...m village is exuding life now. Along the innocent-... of Chennai, India, new casurina saplings are knee...
... care is set to boom following expectations of the...ars. // The four per cent increase equates to abou...bated premium of $1,750, will begin in April. The ...include a wide range of medical services including...
...int flavored sweetener, produced naturally by plan...used as an ingredient in chewing gum, toothpaste, ...ist at Agricultural Research Service (ARS) and col...y engineered bacteria, a modified form of Escheric...
Other Medicine News:Health News:You may Live Long and Think Clear With a Variant Gene 2Health News:Tsunami-Hit Coastal Regions Needs More Relief 2Health News:Xylitol To Be Produced By Genetically Engineered E. Coli 2
(Date:7/23/2008)... on IND-Enabling Work with Protein Therapeutics th...ement System, CAMBRIDGE, Mass., July 23 /PRNewswi...t has initiated a corporate growth plan with the,a...utive officer and the,establishment of its headqua...odruff Emlen, M.D., a co-founder of the company wh...
(Date:7/22/2008)...to Discuss Development Plan Completed Successfully... -- Amarin Corporation,plc (NASDAQ: AMRN ) today ...ials at the U.S. Food and Drug Administration (FDA... for the treatment of,hypertriglyceridemia. Follow...o Phase 3 with AMR101 in hypertriglyceridemia., D...
(Date:7/22/2008)...ISCO, Calif., July 22 /- Hyperion,The...ted patient enrollment,in its Phase 1/2 clinical t...nia scavenging effects of HPN-100 (formally called...in patients with urea cycle disorders,(UCD). The c...ourth quarter,of this year., (Logo: http://www.n...
(Date:7/22/2008)... an Individual,s Genetic Risk Based on Clinical Da...Educational Materials, WALTHAM, Mass., July 22 /P... (Amex: ILI ), today announced the launch of an e... for the company,s Heart Health Genetic Test.,The ...nsona(R) Heart Health,Genetic Test by Quixtar/Amwa...
Breaking Medicine Technology:Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 2Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 3Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 2Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 3Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 2Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 3Childrens Hospital of Orange County Chooses RIVA System For Safe and Efficient IV Preparation 11930 1Childrens Hospital of Orange County Chooses RIVA System For Safe and Efficient IV Preparation 11930 2Data from Two Pivotal Trials of AMRIX a New Once Daily Extended Release Muscle Relaxant Presented at the American Academy of Pain Medicine Meeting 3311 1Data from Two Pivotal Trials of AMRIX a New Once Daily Extended Release Muscle Relaxant Presented at the American Academy of Pain Medicine Meeting 3311 2Data from Two Pivotal Trials of AMRIX a New Once Daily Extended Release Muscle Relaxant Presented at the American Academy of Pain Medicine Meeting 3311 3Data from Two Pivotal Trials of AMRIX a New Once Daily Extended Release Muscle Relaxant Presented at the American Academy of Pain Medicine Meeting 3311 4Rural Hospital Chooses Microsoft Dynamics GP for Healthy Time and Labor Savings 11925 1Rural Hospital Chooses Microsoft Dynamics GP for Healthy Time and Labor Savings 11925 2Rural Hospital Chooses Microsoft Dynamics GP for Healthy Time and Labor Savings 11925 3Rural Hospital Chooses Microsoft Dynamics GP for Healthy Time and Labor Savings 11925 4Technology Transforms Market Research in Pharmaceutical Industry 3309 1Technology Transforms Market Research in Pharmaceutical Industry 3309 2Technology Transforms Market Research in Pharmaceutical Industry 3309 3
...C.--(BUSINESS WIRE)--Jun 12, 2007 - Inspire,Pharma...t,scientists and collaborators related to Inspire ...he European Academy of,Allergology and Clinical Im...eborg, Sweden and at the 30th European Cystic Fibr...16, 2007 in Belek,Turkey., The EAACI Congress inc...
...NDS, Texas--(BUSINESS WIRE)--Jun 11, 2007 - Repros...top-line findings,from its six month study of Proe..., conducted in Europe, enrolled 39,premenopausal w...tudy included three dose levels of Proellex(TM) as...rol was Lucrin(R), a GnRH,agonist also known as Lu...
Other Medicine Technology:Inspire Announces Presentations at Two European Scientific,Conferences 2Inspire Announces Presentations at Two European Scientific,Conferences 3Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care 2Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care 3Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care 4Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care 5Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care 6
Rotating 360 degrees, 3 mm x 7 mm bite.
Right side cutting.
Backward cutting, 3 mm x 7 mm bite, length of shaft 100 mm, overall length 7 inches.
20 mm. Plastic, methylmethacrylate. Supplied sterile.
Medicine Products: